Evolent Health Inc (NYSE:EVH) General Counsel Jonathan Weinberg sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 13th. The shares were sold at an average price of $27.12, for a total transaction of $406,800.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
NYSE:EVH opened at $27.65 on Friday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.59 and a current ratio of 2.59. Evolent Health Inc has a one year low of $10.30 and a one year high of $28.20. The company has a market cap of $2.06 billion, a P/E ratio of -39.50 and a beta of 1.22.
Evolent Health (NYSE:EVH) last posted its earnings results on Tuesday, August 7th. The technology company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.01. Evolent Health had a negative net margin of 9.84% and a negative return on equity of 1.82%. The business had revenue of $144.51 million for the quarter, compared to the consensus estimate of $141.90 million. analysts expect that Evolent Health Inc will post -0.35 earnings per share for the current fiscal year.
A number of equities research analysts have recently weighed in on the stock. Canaccord Genuity raised their price target on shares of Evolent Health from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Thursday. ValuEngine upgraded shares of Evolent Health from a “buy” rating to a “strong-buy” rating in a research note on Friday. KeyCorp restated an “overweight” rating and issued a $32.00 price target (up from $28.00) on shares of Evolent Health in a research note on Thursday. They noted that the move was a valuation call. Cantor Fitzgerald restated a “buy” rating and issued a $37.00 price target on shares of Evolent Health in a research note on Wednesday. Finally, MED raised their price target on shares of Evolent Health from $22.00 to $31.00 and gave the company an “outperform” rating in a research note on Monday, June 18th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $28.67.
Evolent Health Company Profile
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.
Read More: Book Value Per Share – BVPS
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.